Dopamine News and Research

Latest Dopamine News and Research

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.

15 Oct 2012

New insights into how brain responds to extreme stress

Researchers report new insights into how the brain responds to extreme stress, whether from combat, natural disasters, or repeated violent competition. The insights offer hope for detecting and treating several widespread and debilitating neuropsychiatric disorders, and were presented at Neuroscience 2012, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

15 Oct 2012

AAPS recognizes top scientists in pharmaceutical sciences

During the Opening Session of the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, AAPS President David Y. Mitchell, Ph.D., presented the following ground-breaking researchers with awards commemorating their contributions to the pharmaceutical sciences:

15 Oct 2012

Highlights of Mount Sinai research at Neuroscience 2012

Researchers from Mount Sinai School of Medicine are presenting important discoveries on the involvement of the immune system and dopamine cells in the onset of depression at Neuroscience 2012, the Society for Neuroscience's 42nd annual meeting on October 13 -17 in New Orleans, and are available for interviews.

15 Oct 2012

Investigators provide overview of role of dopamine in modulating the immune system

Dopamine is a neurotransmitter that is associated with emotions, movement, and the brain's pleasure and reward system. In the current issue of Advances in Neuroimmune Biology, investigators provide a broad overview of the direct and indirect role of dopamine in modulating the immune system and discuss how recent research has opened up new possibilities for treating diseases such as Parkinson's and Alzheimer's disease, schizophrenia, multiple sclerosis or even the autoimmune disorders.

11 Oct 2012

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

11 Oct 2012

Kynurenic acid levels increased in bipolar patients with psychotic features

Bipolar disorder patients with a history of psychotic features have higher cerebrospinal fluid concentrations of kynurenic acid (KYNA) than those without such features, research shows.

9 Oct 2012

Translational Genomics Research Institute creates new center for rare childhood disorders

The Translational Genomics Research Institute (TGen) today announced the creation of a new center that could have life changing effects on the lives of potentially thousands of children and their families.

6 Oct 2012

Kisspeptin reverses hyperprolactinemia-induced ovarian acyclicity

Kisspeptin neurons appear to play a role in hypogonadotropic anovulation caused by excessive levels of prolactin, research shows.

1 Oct 2012

BioLineRx’s BL-1020 safe and effective in treating schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition.

28 Sep 2012

Teva concludes Asset Transfer Agreement with NeuroSearch

Teva Pharmaceutical Industries Ltd announced today that it has concluded an Asset Transfer Agreement with NeuroSearch A/S of Denmark to purchase all rights, assets and obligations relating to Huntexil (pridopidine / ACR16), a drug candidate being developed for the symptomatic treatment of hand movement, balance and gait disturbances in Huntington disease (HD).

28 Sep 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

Researchers identify mechanism that appears to underlie non-familial form of Parkinson's

Researchers in the Taub Institute at Columbia University Medical Center (CUMC) have identified a mechanism that appears to underlie the common sporadic (non-familial) form of Parkinson's disease, the progressive movement disorder.

26 Sep 2012

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia.

24 Sep 2012

Vanderbilt, Bristol-Myers Squibb partner to advance Parkinson’s disease treatment

Vanderbilt University and Bristol-Myers Squibb Company announced today that they have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinson's disease.

21 Sep 2012

Therapeutic video games can show health-related benefits

Can video games help patients with cancer, diabetes, asthma, depression, autism and Parkinson's disease? A new publication by researchers from the University of Utah, appearing in the Sept 19 issue of the journal Science Translational Medicine, indicates video games can be therapeutic and are already beginning to show health-related benefits.

20 Sep 2012

Dopamine News and Research

Latest Dopamine News and Research

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

New insights into how brain responds to extreme stress

AAPS recognizes top scientists in pharmaceutical sciences

Highlights of Mount Sinai research at Neuroscience 2012

Investigators provide overview of role of dopamine in modulating the immune system

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Kynurenic acid levels increased in bipolar patients with psychotic features

Translational Genomics Research Institute creates new center for rare childhood disorders

Kisspeptin reverses hyperprolactinemia-induced ovarian acyclicity

BioLineRx’s BL-1020 safe and effective in treating schizophrenia

Teva concludes Asset Transfer Agreement with NeuroSearch

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Researchers identify mechanism that appears to underlie non-familial form of Parkinson's

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

Vanderbilt, Bristol-Myers Squibb partner to advance Parkinson’s disease treatment

Therapeutic video games can show health-related benefits

Mephedrone may cause memory loss

UH pharmacologist examines age-related oxidative, inflammatory stress

MAOA gene appears to make women happy

LXRbeta may play a role in prevention and treatment of Parkinson's

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Dopamine News and Research

Latest Dopamine News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in